Semaglutide injection Getty Images 2047465912

ABSTRACT & COMMENTARY

Does Semaglutide Protect Against Adverse Effects from COVID-19?

Name: Relias Media
Price range: $

October 15, 2024

Semaglutide recipients who developed COVID-19 had significant protection against the occurrence of adverse outcomes, including death.

Issue Date: October 15, 2024

Table of Contents

Dr. Stephen Brunton, physician editor, reports he is on the speakers bureau and advisory board for AstraZeneca, Astellas, Bayer, Boehringer Ingelheim, Novo Nordisk, and Renalytix; is on the speakers bureau for Eli Lilly; is on the advisory board for Abbott Diabetes, Phathom, Sanofi, Kowa, Haleon, and Biolinq; and is a stockholder with Paracrine. The relevant financial relationships listed for this individual have been mitigated. None of the remaining planners or authors for this educational activity have relevant financial relationships to disclose with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

Subscription Publication Books & Study Guides Group & Site Licenses State CME/CE Requirements